The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide

A. E. Fung, Philip J Rosenfeld, E. Reichel

Research output: Contribution to journalArticle

489 Citations (Scopus)

Abstract

Aim: Off-label intravitreal injections of bevacizumab (Avastin) have been given for the treatment of neovascular and exudative ocular diseases since May 2005. Since then, the use of intravitreal bevacizumab has spread worldwide, but the drug-related adverse events associated with its use have been reported only in a few retrospective reviews. The International Intravitreal Bevacizumab Safety Survey was initiated to gather timely information regarding adverse events from doctors around the world via the internet. Methods: An internet-based survey was designed to identify adverse events associated with intravitreal bevacizumab treatment. The survey web address was disseminated to the international vitreoretinal community via email. Rates of adverse events were calculated from participant responses. Results: 70 centres from 12 countries reported on 7113 injections given to 5228 patients. Doctor-reported adverse events included corneal abrasion, lens injury, endophthalmitis, retinal detachment, inflammation or uveitis, cataract progression, acute vision loss, central retinal artery occlusion, subretinal haemorrhage, retinal pigment epithelium tears, blood pressure elevation, transient ischaemic attack, cerebrovascular accident and death. None of the adverse event rates exceeded 0.21%. Conclusion: Intravitreal bevacizumab is being used globally for ocular diseases. Self-reporting of adverse events after intravitreal bevacizumab injections did not show an increased rate of potential drug-related ocular or systemic events. These short-term results suggest that intravitreal bevacizumab seems to be safe.

Original languageEnglish
Pages (from-to)1344-1349
Number of pages6
JournalBritish Journal of Ophthalmology
Volume90
Issue number11
DOIs
StatePublished - Nov 1 2006

Fingerprint

Internet
Safety
Pharmaceutical Preparations
Intravitreal Injections
Eye Diseases
Retinal Artery Occlusion
Endophthalmitis
Surveys and Questionnaires
Bevacizumab
Retinal Pigment Epithelium
Transient Ischemic Attack
Uveitis
Retinal Detachment
Drug-Related Side Effects and Adverse Reactions
Cataract
Lenses
Stroke
Hemorrhage
Blood Pressure
Inflammation

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The International Intravitreal Bevacizumab Safety Survey : Using the internet to assess drug safety worldwide. / Fung, A. E.; Rosenfeld, Philip J; Reichel, E.

In: British Journal of Ophthalmology, Vol. 90, No. 11, 01.11.2006, p. 1344-1349.

Research output: Contribution to journalArticle

@article{b37fb45c7ebc419991680aee715c63af,
title = "The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide",
abstract = "Aim: Off-label intravitreal injections of bevacizumab (Avastin) have been given for the treatment of neovascular and exudative ocular diseases since May 2005. Since then, the use of intravitreal bevacizumab has spread worldwide, but the drug-related adverse events associated with its use have been reported only in a few retrospective reviews. The International Intravitreal Bevacizumab Safety Survey was initiated to gather timely information regarding adverse events from doctors around the world via the internet. Methods: An internet-based survey was designed to identify adverse events associated with intravitreal bevacizumab treatment. The survey web address was disseminated to the international vitreoretinal community via email. Rates of adverse events were calculated from participant responses. Results: 70 centres from 12 countries reported on 7113 injections given to 5228 patients. Doctor-reported adverse events included corneal abrasion, lens injury, endophthalmitis, retinal detachment, inflammation or uveitis, cataract progression, acute vision loss, central retinal artery occlusion, subretinal haemorrhage, retinal pigment epithelium tears, blood pressure elevation, transient ischaemic attack, cerebrovascular accident and death. None of the adverse event rates exceeded 0.21{\%}. Conclusion: Intravitreal bevacizumab is being used globally for ocular diseases. Self-reporting of adverse events after intravitreal bevacizumab injections did not show an increased rate of potential drug-related ocular or systemic events. These short-term results suggest that intravitreal bevacizumab seems to be safe.",
author = "Fung, {A. E.} and Rosenfeld, {Philip J} and E. Reichel",
year = "2006",
month = "11",
day = "1",
doi = "10.1136/bjo.2006.099598",
language = "English",
volume = "90",
pages = "1344--1349",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - The International Intravitreal Bevacizumab Safety Survey

T2 - Using the internet to assess drug safety worldwide

AU - Fung, A. E.

AU - Rosenfeld, Philip J

AU - Reichel, E.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Aim: Off-label intravitreal injections of bevacizumab (Avastin) have been given for the treatment of neovascular and exudative ocular diseases since May 2005. Since then, the use of intravitreal bevacizumab has spread worldwide, but the drug-related adverse events associated with its use have been reported only in a few retrospective reviews. The International Intravitreal Bevacizumab Safety Survey was initiated to gather timely information regarding adverse events from doctors around the world via the internet. Methods: An internet-based survey was designed to identify adverse events associated with intravitreal bevacizumab treatment. The survey web address was disseminated to the international vitreoretinal community via email. Rates of adverse events were calculated from participant responses. Results: 70 centres from 12 countries reported on 7113 injections given to 5228 patients. Doctor-reported adverse events included corneal abrasion, lens injury, endophthalmitis, retinal detachment, inflammation or uveitis, cataract progression, acute vision loss, central retinal artery occlusion, subretinal haemorrhage, retinal pigment epithelium tears, blood pressure elevation, transient ischaemic attack, cerebrovascular accident and death. None of the adverse event rates exceeded 0.21%. Conclusion: Intravitreal bevacizumab is being used globally for ocular diseases. Self-reporting of adverse events after intravitreal bevacizumab injections did not show an increased rate of potential drug-related ocular or systemic events. These short-term results suggest that intravitreal bevacizumab seems to be safe.

AB - Aim: Off-label intravitreal injections of bevacizumab (Avastin) have been given for the treatment of neovascular and exudative ocular diseases since May 2005. Since then, the use of intravitreal bevacizumab has spread worldwide, but the drug-related adverse events associated with its use have been reported only in a few retrospective reviews. The International Intravitreal Bevacizumab Safety Survey was initiated to gather timely information regarding adverse events from doctors around the world via the internet. Methods: An internet-based survey was designed to identify adverse events associated with intravitreal bevacizumab treatment. The survey web address was disseminated to the international vitreoretinal community via email. Rates of adverse events were calculated from participant responses. Results: 70 centres from 12 countries reported on 7113 injections given to 5228 patients. Doctor-reported adverse events included corneal abrasion, lens injury, endophthalmitis, retinal detachment, inflammation or uveitis, cataract progression, acute vision loss, central retinal artery occlusion, subretinal haemorrhage, retinal pigment epithelium tears, blood pressure elevation, transient ischaemic attack, cerebrovascular accident and death. None of the adverse event rates exceeded 0.21%. Conclusion: Intravitreal bevacizumab is being used globally for ocular diseases. Self-reporting of adverse events after intravitreal bevacizumab injections did not show an increased rate of potential drug-related ocular or systemic events. These short-term results suggest that intravitreal bevacizumab seems to be safe.

UR - http://www.scopus.com/inward/record.url?scp=33750296920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750296920&partnerID=8YFLogxK

U2 - 10.1136/bjo.2006.099598

DO - 10.1136/bjo.2006.099598

M3 - Article

C2 - 16854824

AN - SCOPUS:33750296920

VL - 90

SP - 1344

EP - 1349

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 11

ER -